David Palesch
Overview
Explore the profile of David Palesch including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
352
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zanoni M, Palesch D, Pinacchio C, Statzu M, Tharp G, Paiardini M, et al.
PLoS Pathog
. 2020 Sep;
16(9):e1008821.
PMID: 32941545
MHC-I-restricted, virus-specific cytotoxic CD8+ T cells (CTLs) may control human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) replication via the recognition and killing of productively infected CD4+ T cells....
2.
Rabezanahary H, Moukambi F, Palesch D, Clain J, Racine G, Andreani G, et al.
Mucosal Immunol
. 2019 Nov;
13(1):149-160.
PMID: 31723251
Whereas antiretroviral therapy (ART) suppresses viral replication, ART discontinuation results in viral rebound, indicating the presence of viral reservoirs (VRs) established within lymphoid tissues. Herein, by sorting CD4 T-cell subsets...
3.
Zanoni M, Palesch D, Silvestri G
Nat Microbiol
. 2018 May;
3(6):648-649.
PMID: 29784974
No abstract available.
4.
Palesch D, Bosinger S, Mavigner M, Billingsley J, Mattingly C, Carnathan D, et al.
J Virol
. 2018 May;
92(14).
PMID: 29720521
The major obstacle to human immunodeficiency type 1 (HIV-1) eradication is a reservoir of latently infected cells that persists despite long-term antiretroviral therapy (ART) and causes rapid viral rebound if...
5.
Ferrando-Martinez S, Moysi E, Pegu A, Andrews S, Makamdop K, Ambrozak D, et al.
J Clin Invest
. 2018 Apr;
128(5):2089-2103.
PMID: 29664020
LN follicles constitute major reservoir sites for HIV/SIV persistence. Cure strategies could benefit from the characterization of CD8+ T cells able to access and eliminate HIV-infected cells from these areas....
6.
Palesch D, Bosinger S, Tharp G, Vanderford T, Paiardini M, Chahroudi A, et al.
Nature
. 2018 Jan;
553(7686):77-81.
PMID: 29300007
In contrast to infections with human immunodeficiency virus (HIV) in humans and simian immunodeficiency virus (SIV) in macaques, SIV infection of a natural host, sooty mangabeys (Cercocebus atys), is non-pathogenic...
7.
Giese M, Turiello N, Molenda N, Palesch D, Meid A, Schroeder R, et al.
Oncotarget
. 2016 Nov;
7(46):74602-74611.
PMID: 27806341
Major histocompatibility complex (MHC) class I molecules present antigenic peptides to cytotoxic T cells. During an adaptive immune response, MHC molecules are regulated by several mechanisms including lipopolysaccharide (LPS) and...
8.
Palesch D, Boldt F, Muller J, Eisele K, Sturzel C, Wu Y, et al.
Chembiochem
. 2016 May;
17(16):1504-8.
PMID: 27239020
Retroviral vectors are common tools for introducing genes into the genome of a cell. However, low transduction rates are a major limitation in retroviral gene transfer, especially in clinical applications....
9.
Cartwright E, Palesch D, Mavigner M, Paiardini M, Chahroudi A, Silvestri G
J Virol
. 2016 May;
90(15):6699-6708.
PMID: 27170752
Unlabelled: Treatment of human immunodeficiency virus (HIV) infection with antiretroviral therapy (ART) has significantly improved prognosis. Unfortunately, interruption of ART almost invariably results in viral rebound, attributed to a pool...
10.
Eipper S, Steiner R, Lesner A, Sienczyk M, Palesch D, Halatsch M, et al.
PLoS One
. 2016 Mar;
11(3):e0151509.
PMID: 26986619
Protease-mediated degradation of proteins is critical in a plethora of physiological processes. Neutrophils secrete serine proteases including cathepsin G (CatG), neutrophile elastase (NE), and proteinase 3 (PR3) together with lactoferrin...